尊龙

Be the most trusted biotech company

2025-03-05

Henlius Successfully Holds First In-Person Investigator Meeting in Japan, Accelerating Global Clinical Research for Innovative Pipeline
2025-02-26

Updated Long-term Survival Results from the International Multicenter Phase 3 Clinical Trial of HANQUYOU Published in The Breast
2025-02-19

Henlius Bevacizumab Secures First Overseas Approval, Accelerating Henlius' Expansion into Latin American Market
2025-02-18

Clinical and Translational Science Publishes Phase 1 Clinical Results of Henlius’ HLX14
2025-02-12

Phase 3 MRCT Results of Denosumab Biosimilar HLX14 Released at ORS 2025
2025-02-10

First Subject Dosed for a Phase 2 Clinical Trial of Henlius’ PD-L1-Targeting ADC HLX43
2025-02-06

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
2025-02-05

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2025-02-02

US FDA Accepts Biologics License Application (BLA) for HLX11, Biosimilar Candidate of Perjeta® (pertuzumab)